Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-up of A9-DPC in Parkinson's Disease
NCT06477744Phase 2Active, not recruiting
- Sponsor
- S.Biomedics
- Start
- Sep 2023
- Primary completion
- Feb 2029
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of TED-A9 in Parkinson's disease (PD) (2 arms), sponsored by S.Biomedics. Primary endpoint: Adverse Event of Special Interests at 5 years. Started Sep 2023; status: active, not recruiting.
02
Drugs
TED-A9
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06477744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06477744.